STOCKHOLM, Sweden, 20th September 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) has signed an agreement with Cliantha Research to conduct a phase III study with the drug candidate AKP02G2, for the treatment of psoriasis. The study is expected to begin recruitment of patients in the first half of 2024 and Lipidor […]
STOCKHOLM, Sweden, 23 August 2023 – In Lipidor's interim report for the second quarter 2023, published today at 08:30, incorrect figures were reported for the comparison period Jan-Jun 2022. Instead, Jan-Jun 2021 figures were included. The corrected quarterly report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly […]
STOCKHOLM, Sweden, 23 August 2023 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June 2023. The report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly report (in Swedish) click here: https://lipidor.se/lipidor-ab-delarsrapport-q2-2023/ Summary of interim report […]
STOCKHOLM, Sweden, 29th June 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that financing of SEK 2 million is being provided through the divestment of holdings in the affiliated company Emollivet. A short-term loan of 1 million SEK has also been signed. On 22nd June, it was announced that the Swedish […]
STOCKHOLM, Sweden, 22nd June 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the Swedish Medical Products Agency (“MPA”) considers that AKP02G2, a modified version of the company's drug candidate AKP02 for the treatment of psoriasis, can be used in a new Phase III clinical study. This means that no […]
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Lipidor AB (publ) (the “Company”) on 8 June 2023 in Stockholm. Adoption of income statement and balance sheet and discharge from liabilityThe AGM resolved to adopt the income statement for the financial year 2022 as well as the balance sheet as of […]
STOCKHOLM, Sweden, 26th May 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) is targeting a new Phase III study of the drug candidate AKP02 in 2024. Data from the earlier completed clinical study with AKP02 has been analyzed, and a way forward is clear. On 28th October 2022, Lipidor announced that the […]
STOCKHOLM, Sweden, 11 May 2023 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – March 2023. The report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly report (in Swedish) click here: https://lipidor.se/lipidor-ab-delarsrapport-q1-2023/ Summary of interim report […]
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Annual General Meeting (the “AGM”) on 8 June 2023 at 15.00 CEST at Fredersen Advokatbyrå, Birger Jarlsgatan […]
STOCKHOLM, Sweden, 26th April 2023 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the financial year 2022. The report is available on the company's website lipidor.se and in the attached pdf (in Swedish). To read the report in full (in Swedish) click here: https://lipidor.se/arsredovisning-2022/ The information was […]